Haploinsufficiency due to a novel ACO2 deletion causes mitochondrial dysfunction in fibroblasts from a patient with dominant optic nerve atrophy.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
07 10 2020
Historique:
received: 11 11 2019
accepted: 02 09 2020
entrez: 8 10 2020
pubmed: 9 10 2020
medline: 15 12 2020
Statut: epublish

Résumé

ACO2 is a mitochondrial protein, which is critically involved in the function of the tricarboxylic acid cycle (TCA), the maintenance of iron homeostasis, oxidative stress defense and the integrity of mitochondrial DNA (mtDNA). Mutations in the ACO2 gene were identified in patients suffering from a broad range of symptoms, including optic nerve atrophy, cortical atrophy, cerebellar atrophy, hypotonia, seizures and intellectual disabilities. In the present study, we identified a heterozygous 51 bp deletion (c.1699_1749del51) in ACO2 in a family with autosomal dominant inherited isolated optic atrophy. A complementation assay using aco1-deficient yeast revealed a growth defect for the mutant ACO2 variant substantiating a pathogenic effect of the deletion. We used patient-derived fibroblasts to characterize cellular phenotypes and found a decrease of ACO2 protein levels, while ACO2 enzyme activity was not affected compared to two age- and gender-matched control lines. Several parameters of mitochondrial function, including mitochondrial morphology, mitochondrial membrane potential or mitochondrial superoxide production, were not changed under baseline conditions. However, basal respiration, maximal respiration, and spare respiratory capacity were reduced in mutant cells. Furthermore, we observed a reduction of mtDNA copy number and reduced mtDNA transcription levels in ACO2-mutant fibroblasts. Inducing oxidative stress led to an increased susceptibility for cell death in ACO2-mutant fibroblasts compared to controls. Our study reveals that a monoallelic mutation in ACO2 is sufficient to promote mitochondrial dysfunction and increased vulnerability to oxidative stress as main drivers of cell death related to optic nerve atrophy.

Identifiants

pubmed: 33028849
doi: 10.1038/s41598-020-73557-4
pii: 10.1038/s41598-020-73557-4
pmc: PMC7541502
doi:

Substances chimiques

DNA, Mitochondrial 0
ACO2 protein, human EC 4.2.1.3
Aconitate Hydratase EC 4.2.1.3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16736

Références

Biousse, V. & Newman, N. J. Hereditary optic neuropathies. Ophthalmol. Clin. N. Am. 14, 547–568 (2001).
doi: 10.1016/S0896-1549(05)70252-2
Newman, N. J. & Biousse, V. Hereditary optic neuropathies. Eye (Lond). 18, 1144–1160 (2004).
pubmed: 15534600 doi: 10.1038/sj.eye.6701591
Yu-Wai-Man, P. et al. Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies. Ophthalmology 118, 558–563 (2011).
pubmed: 21036400 doi: 10.1016/j.ophtha.2010.07.029
Neuhann, T. & Rautenstrauss, B. Genetic and phenotypic variability of optic neuropathies. Expert Rev. Neurother. 13, 357–367 (2013).
pubmed: 23545052 doi: 10.1586/ern.13.19
Metodiev, M. D. et al. Mutations in the tricarboxylic acid cycle enzyme, aconitase 2, cause either isolated or syndromic optic neuropathy with encephalopathy and cerebellar atrophy. J. Med. Genet. 51, 834–838 (2014).
pubmed: 25351951 doi: 10.1136/jmedgenet-2014-102532
Wissinger, B. Genetic causes and genetic diagnostic testing of inherited optic atrophies. Klin. Monbl. Augenheilkd. 235, 1235–1241 (2018).
pubmed: 30458563 doi: 10.1055/a-0759-2094
Chun, B. Y. & Rizzo, J. F. Dominant optic atrophy and Leber’s hereditary optic neuropathy: Update on clinical features and current therapeutic approaches. Semin. Pediatr. Neurol. 24, 129–134 (2017).
pubmed: 28941528 doi: 10.1016/j.spen.2017.06.001 pmcid: 28941528
Lenaers, G. et al. Dominant optic atrophy. Orphanet. J. Rare Dis. 7, 46 (2012).
pubmed: 22776096 pmcid: 3526509 doi: 10.1186/1750-1172-7-46
Spiegel, R. et al. Infantile cerebellar-retinal degeneration associated with a mutation in mitochondrial aconitase, ACO2. Am. J. Hum. Genet. 90, 518–523 (2012).
pubmed: 22405087 pmcid: 3309186 doi: 10.1016/j.ajhg.2012.01.009
Sadat, R. et al. Functional cellular analyses reveal energy metabolism defect and mitochondrial DNA depletion in a case of mitochondrial aconitase deficiency. Mol. Genet. Metab. 118, 28–34 (2016).
pubmed: 26992325 pmcid: 4833660 doi: 10.1016/j.ymgme.2016.03.004
Srivastava, S. et al. Increased survival and partly preserved cognition in a patient with ACO2-related disease secondary to a novel variant. J. Child Neurol. 32, 840–845 (2017).
pubmed: 28545339 pmcid: 5515684 doi: 10.1177/0883073817711527
Kelman, J. C. et al. A sibling study of isolated optic neuropathy associated with novel variants in the ACO2 gene. Ophthal. Genet. 39, 648–651 (2018).
pubmed: 30118607 doi: 10.1080/13816810.2018.1509353 pmcid: 30118607
Marelli, C. et al. ACO2 mutations: A novel phenotype associating severe optic atrophy and spastic paraplegia. Neurol. Genet. 4, e225 (2018).
pubmed: 29564393 pmcid: 5860906 doi: 10.1212/NXG.0000000000000225
Sharkia, R. et al. Clinical, radiological, and genetic characteristics of 16 patients with ACO2 gene defects: Delineation of an emerging neurometabolic syndrome. J. Inherit. Metab. Dis. 42, 264–275 (2019).
pubmed: 30689204 doi: 10.1002/jimd.12022 pmcid: 30689204
Jung, S.-J., Seo, Y., Lee, K.-C., Lee, D. & Roe, J.-H. Essential function of Aco2, a fusion protein of aconitase and mitochondrial ribosomal protein bL21, in mitochondrial translation in fission yeast. FEBS Lett. 589, 822–828 (2015).
pubmed: 25724335 doi: 10.1016/j.febslet.2015.02.015 pmcid: 25724335
Kennedy, M. C., Emptage, M. H., Dreyer, J. L. & Beinert, H. The role of iron in the activation-inactivation of aconitase. J. Biol. Chem. 258, 11098–11105 (1983).
pubmed: 6309829 pmcid: 6309829
Robbins, A. H. & Stout, C. D. Iron-sulfur cluster in aconitase. Crystallographic evidence for a three-iron center. J. Biol. Chem. 260, 2328–2333 (1985).
pubmed: 3972791 pmcid: 3972791
Rouault, T. A. & Tong, W.-H. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat. Rev. Mol. Cell Biol. 6, 345–351 (2005).
pubmed: 15803140 doi: 10.1038/nrm1620 pmcid: 15803140
Melefors, O. & Hentze, M. W. Translational regulation by mRNA/protein interactions in eukaryotic cells: Ferritin and beyond. BioEssays 15, 85–90 (1993).
pubmed: 8471060 doi: 10.1002/bies.950150203 pmcid: 8471060
Vasquez-Vivar, J., Kalyanaraman, B. & Kennedy, M. C. Mitochondrial aconitase is a source of hydroxyl radical. An electron spin resonance investigation. J. Biol. Chem. 275, 14064–14069 (2000).
pubmed: 10799480 doi: 10.1074/jbc.275.19.14064 pmcid: 10799480
Tong, W.-H. & Rouault, T. A. Metabolic regulation of citrate and iron by aconitases: Role of iron-sulfur cluster biogenesis. Biometals 20, 549–564 (2007).
pubmed: 17205209 doi: 10.1007/s10534-006-9047-6 pmcid: 17205209
Bulteau, A.-L., Ikeda-Saito, M. & Szweda, L. I. Redox-dependent modulation of aconitase activity in intact mitochondria. Biochemistry 42, 14846–14855 (2003).
pubmed: 14674759 doi: 10.1021/bi0353979 pmcid: 14674759
Yan, L. J., Levine, R. L. & Sohal, R. S. Oxidative damage during aging targets mitochondrial aconitase. Proc. Natl. Acad. Sci. U.S.A. 94, 11168–11172 (1997).
pubmed: 9326580 pmcid: 23404 doi: 10.1073/pnas.94.21.11168
Williams, M. D. et al. Increased oxidative damage is correlated to altered mitochondrial function in heterozygous manganese superoxide dismutase knockout mice. J. Biol. Chem. 273, 28510–28515 (1998).
pubmed: 9774481 doi: 10.1074/jbc.273.43.28510 pmcid: 9774481
Chen, X. J., Wang, X., Kaufman, B. A. & Butow, R. A. Aconitase couples metabolic regulation to mitochondrial DNA maintenance. Science 307, 714–717 (2005).
pubmed: 15692048 doi: 10.1126/science.1106391 pmcid: 15692048
Lin, G., Brownsey, R. W. & MacLeod, K. M. Regulation of mitochondrial aconitase by phosphorylation in diabetic rat heart. Cell. Mol. Life Sci. 66, 919–932 (2009).
pubmed: 19153662 doi: 10.1007/s00018-009-8696-3 pmcid: 19153662
Tsui, K.-H., Feng, T.-H., Lin, Y.-F., Chang, P.-L. & Juang, H.-H. p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. Prostate 71, 62–70 (2011).
pubmed: 20607720 doi: 10.1002/pros.21222 pmcid: 20607720
Wang, P. et al. Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer. Med. Oncol. 30, 552 (2013).
pubmed: 23550275 doi: 10.1007/s12032-013-0552-5 pmcid: 23550275
Lauble, H., Kennedy, M. C., Beinert, H. & Stout, C. D. Crystal structures of aconitase with isocitrate and nitroisocitrate bound. Biochemistry 31, 2735–2748 (1992).
pubmed: 1547214 doi: 10.1021/bi00125a014 pmcid: 1547214
Edgar, R. C. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792–1797 (2004).
pubmed: 15034147 pmcid: 390337 doi: 10.1093/nar/gkh340
Fukuhara, H. The Kluyver effect revisited. FEMS Yeast Res. 3, 327–331 (2003).
pubmed: 12748045 doi: 10.1016/S1567-1356(03)00112-0
Regev-Rudzki, N., Karniely, S., Ben-Haim, N. N. & Pines, O. Yeast aconitase in two locations and two metabolic pathways: Seeing small amounts is believing. Mol. Biol. Cell 16, 4163–4171 (2005).
pubmed: 15975908 pmcid: 1196327 doi: 10.1091/mbc.e04-11-1028
Bouwkamp, C. G. et al. ACO2 homozygous missense mutation associated with complicated hereditary spastic paraplegia. Neurol. Genet. 4, e223 (2018).
pubmed: 29577077 pmcid: 5863690 doi: 10.1212/NXG.0000000000000223
Cantu, D., Fulton, R. E., Drechsel, D. A. & Patel, M. Mitochondrial aconitase knockdown attenuates paraquat-induced dopaminergic cell death via decreased cellular metabolism and release of iron and H
pubmed: 21517855 pmcid: 3182850 doi: 10.1111/j.1471-4159.2011.07290.x
Kim, S.-J. et al. Mitochondria-targeted Ogg1 and aconitase-2 prevent oxidant-induced mitochondrial DNA damage in alveolar epithelial cells. J. Biol. Chem. 289, 6165–6176 (2014).
pubmed: 24429287 pmcid: 3937682 doi: 10.1074/jbc.M113.515130
Yu-Wai-Man, P., Votruba, M., Moore, A. T. & Chinnery, P. F. Treatment strategies for inherited optic neuropathies: Past, present and future. Eye (Lond.) 28, 521–537 (2014).
doi: 10.1038/eye.2014.37
Fraser, J. A., Biousse, V. & Newman, N. J. The neuro-ophthalmology of mitochondrial disease. Surv. Ophthalmol. 55, 299–334 (2020).
doi: 10.1016/j.survophthal.2009.10.002
Van Bergen, N. J. et al. Mitochondrial oxidative phosphorylation compensation may preserve vision in patients with OPA1-linked autosomal dominant optic atrophy. PLoS ONE 6, e21347 (2011).
pubmed: 21731710 pmcid: 3120866 doi: 10.1371/journal.pone.0021347
Del Dotto, V. et al. OPA1 Isoforms in the hierarchical organization of mitochondrial functions. Cell Rep. 19, 2557–2571 (2017).
pubmed: 28636943 doi: 10.1016/j.celrep.2017.05.073
Del Dotto, V., Fogazza, M., Carelli, V., Rugolo, M. & Zanna, C. Eight human OPA1 isoforms, long and short: What are they for?. Biochim. Biophys. acta. Bioenergy 1859, 263–269 (2018).
doi: 10.1016/j.bbabio.2018.01.005
Millet, A. M. C. et al. Loss of functional OPA1 unbalances redox state: implications in dominant optic atrophy pathogenesis. Ann. Clin. Transl. Neurol. 3, 408–421 (2016).
pubmed: 27547769 pmcid: 4891995 doi: 10.1002/acn3.305
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168 pmcid: 19451168 doi: 10.1093/bioinformatics/btp324
Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 2723002 pmcid: 2723002 doi: 10.1093/bioinformatics/btp352
Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: A pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).
pubmed: 19561018 pmcid: 2781750 doi: 10.1093/bioinformatics/btp394
Plagnol, V. et al. A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics 28, 2747–2754 (2012).
pubmed: 22942019 pmcid: 3476336 doi: 10.1093/bioinformatics/bts526
Sali, A., Potterton, L., Yuan, F., van Vlijmen, H. & Karplus, M. Evaluation of comparative protein modeling by MODELLER. Proteins 23, 318–326 (1995).
pubmed: 8710825 doi: 10.1002/prot.340230306 pmcid: 8710825
Chen, V. B. et al. MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr. D. Biol. Crystallogr. 66, 12–21 (2010).
pubmed: 20057044 doi: 10.1107/S0907444909042073 pmcid: 20057044
Hipp, G. et al. The Luxembourg Parkinson’s study: A comprehensive approach for stratification and early diagnosis. Front. Aging Neurosci. 10, 326 (2018).
pubmed: 30420802 pmcid: 6216083 doi: 10.3389/fnagi.2018.00326
Grünewald, A. et al. Differential effects of PINK1 nonsense and missense mutations on mitochondrial function and morphology. Exp. Neurol. 219, 266–273 (2009).
pubmed: 19500570 doi: 10.1016/j.expneurol.2009.05.027 pmcid: 19500570
Grünewald, A. et al. Mitochondrial DNA depletion in respiratory chain-deficient Parkinson disease neurons. Ann. Neurol. 79, 366–378 (2016).
pubmed: 26605748 pmcid: 4819690 doi: 10.1002/ana.24571
Nicholls, T. J. & Minczuk, M. In D-loop: 40 years of mitochondrial 7S DNA. Exp. Gerontol. 56, 175–181 (2014).
pubmed: 24709344 doi: 10.1016/j.exger.2014.03.027 pmcid: 24709344
Rogers, G. W. et al. High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. PLoS ONE 6, e21746 (2011).
pubmed: 21799747 pmcid: 3143121 doi: 10.1371/journal.pone.0021746
Fitzgerald, J. C. et al. Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinson’s disease. Brain 140, 2444–2459 (2017).
pubmed: 29050400 doi: 10.1093/brain/awx202 pmcid: 29050400

Auteurs

Marie Anne-Catherine Neumann (MA)

Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Faculty of Medicine, RWTH Aachen University, Aachen, Germany.

Dajana Grossmann (D)

Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. dajana.grossmann@med.uni-rostock.de.

Simone Schimpf-Linzenbold (S)

CeGaT GmbH and Praxis für Humangenetik Tübingen, Tübingen, Germany.
Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tuebingen, Tübingen, Germany.

Dana Dayan (D)

School of Neurobiology, Biochemistry and Biophysics, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.

Katarina Stingl (K)

Centre for Ophthalmology, University Eye Hospital, University of Tübingen, Tübingen, Germany.

Reut Ben-Menachem (R)

Department of Microbiology and Molecular Genetics, IMRIC, Faculty of Medicine, Hebrew University, Jerusalem, Israel.

Ophry Pines (O)

Department of Microbiology and Molecular Genetics, IMRIC, Faculty of Medicine, Hebrew University, Jerusalem, Israel.
NUS-HUJ-CREATE Program and the Department of Microbiology, School of Medicine, National University of Singapore, Singapore, Singapore.

François Massart (F)

Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Sylvie Delcambre (S)

Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Jenny Ghelfi (J)

Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Jill Bohler (J)

Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Tim Strom (T)

Institute of Human Genetics, Helmholtz Zentrum Muenchen, Neuherberg, Germany.

Amit Kessel (A)

School of Neurobiology, Biochemistry and Biophysics, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.

Abdussalam Azem (A)

School of Neurobiology, Biochemistry and Biophysics, George S Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.

Ludger Schöls (L)

Department of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.

Anne Grünewald (A)

Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.

Bernd Wissinger (B)

Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tuebingen, Tübingen, Germany.
Centre for Ophthalmology, University Eye Hospital, University of Tübingen, Tübingen, Germany.

Rejko Krüger (R)

Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg. rejko.krueger@uni.lu.
Transversal Translational Medicine, Luxembourg Institute of Health (LIH), Strassen, Luxembourg. rejko.krueger@uni.lu.
Parkinson Research Clinic, Centre Hospitalier de Luxembourg (CHL), Luxembourg, Luxembourg. rejko.krueger@uni.lu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH